Alyssa Noll

Alyssa Noll

Auto-generated profile, based on publicly available information

Alyssa Noll

Ben Towne Center for Childhood Cancer and Blood Disorders Research, Seattle Children's Research Institute, Seattle, WA

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2015 in Cell
Verified
Journal Article
Closed access
HVHumsa S. Venkatesh
Humsa S. Venkatesh
TJTessa B. Johung
Tessa B. Johung
VCViola Caretti
Viola Caretti
ANAlyssa Noll
Alyssa Noll
YTYujie Tang
Yujie Tang
MMMichelle Monje
Michelle Monje

19 August 2023 in Neoplasia
Verified
Journal Article
Open access
ANAlyssa Noll
Alyssa Noll
CMCarrie Myers
Carrie Myers
MBMatthew C. Biery
Matthew C. Biery
MMMichael Meechan
Michael Meechan
STSophie Tahiri
Sophie Tahiri
NVNicholas A Vitanza
Nicholas A Vitanza
Constitutional mismatch repair deficiency (CMMRD) is a cancer predisposition syndrome associated with the development of hypermutant pediatric high-grade glioma, and confers a poor prognosis. While therapeutic histone deacetylase (HDAC) inhibition of diffuse intrinsic pontine glioma (DIPG) has been reported; here, we use a clinically relevant biopsy-derived hypermutant DIPG model (PBT-24FH) and a CRISPR-Cas9 induced genetic model to evaluate the efficacy of HDAC inhibition against hypermutant DIPG. We screened PBT-24FH cells for sensitivity to a panel of HDAC inhibitors (HDACis) in vitro, identifying two HDACis associated with low nanomolar IC50s, quisinostat (27 nM) and romidepsin (2 nM). In vivo, quisinostat proved more efficacious, inducing near-complete tumor regression in a PBT-24FH flank model. RNA sequencing revealed significant quisinostat-driven changes in gene expression, including upregulation of neural and pro-inflammatory genes. To validate the observed potency of quisinostat in vivo against additional hypermutant DIPG models, we tested quisinostat in genetically-induced mismatch repair (MMR)-deficient DIPG flank tumors, demonstrating that loss of MMR function increases sensitivity to quisinostat in vivo. Here, we establish the preclinical efficacy of quisinostat against hypermutant DIPG, supporting further investigation of epigenetic targeting of hypermutant pediatric cancers with the potential for clinical translation. These findings support further investigation of HDAC inhibitors against pontine high-grade gliomas, beyond only those with histone mutations, as well as against other hypermutant central nervous system tumors.

15 April 2026 in Blood Neoplasia
Verified
Journal Article
Open access
SMShelli M. Morris
Shelli M. Morris
KPKristina Pilat
Kristina Pilat
EGEmily J. Girard
Emily J. Girard
ANAlyssa Noll
Alyssa Noll
LALisa S. Ang
Lisa S. Ang
JOJames M. Olson
James M. Olson